PRODUCT PIPLINE
| Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 | Market | |
|---|---|---|---|---|---|---|
| ONCOLOGY | ||||||
| Acromegaly Octreotide (C2L) [1] |
 |
|
|
|
 |
|
| Prostate Cancer Goserelin |
|
|
|
 |
||
| Cancer NGR-Delivery Technology |
|
|
||||
| VIROLOGY | ||||||
| HIV/AIDS | ||||||
| Protease Inhibitors |  |
|
 |
|||
| Integrase Inhibitors | |
|||||
| Entry Inhibitors | |
|||||
| HCV | ||||||
| Polymerase Inhibitors | |
|||||
| Entry Inhibitors | |
|||||
| Influenza A | ||||||
| Influenza M2 Proton Channel Inhibitors | |
|||||
(1) Licensed to TEVA (France, Germany, Benelux, Spain, Scandinavia), Archimedes Pharma (U.K.), Gerolymatos (Greece, Turkey, other countries), Kwidza Pharma (Austria), Omega (Canada, Egypt), Pharmis (Portugal, Brazil), Shin Poong (Korea), Genepharm Limited (Austrailia and New Zealand) and others